Runben Biotechnology (SH:603193) Shang Hai Zheng Quan Bao·2025-07-10 20:12Summary of Key Points Core Viewpoint - JNRY VIII HK Holdings Limited, a major shareholder of Runben Biotechnology Co., Ltd., has completed a share reduction plan, selling a total of 3,608,400 shares, which is 0.89% of the company's total share capital [2][3][4]. Group 1: Shareholder Holding Situation - Before the reduction plan, JNRY VIII held 22,252,566 shares, accounting for 5.50% of the total share capital of the company [2]. Group 2: Reduction Plan Implementation Results - The reduction plan announced on March 19, 2025, allowed JNRY VIII to reduce up to 12,137,799 shares (3.00% of total share capital) through both centralized bidding and block trading [3]. - The actual reduction was completed within the specified timeframe, and the total shares reduced were consistent with the previously disclosed plan [4]. - The reduction included a maximum of 4,045,933 shares through centralized bidding (1.00% of total share capital) and 8,091,866 shares through block trading (2.00% of total share capital) [3].